• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aspire Biopharma Holdings, Inc. - Common Stock (NQ:ASBP)

1.050 -0.080 (-7.08%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aspire Biopharma Holdings, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026
March 12, 2026
Via ACCESS Newswire
News headline image
Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack
March 10, 2026
Via ACCESS Newswire
News headline image
Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief
March 03, 2026
Via ACCESS Newswire
News headline image
Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship
February 25, 2026
Via ACCESS Newswire
News headline image
Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements
February 20, 2026
Via ACCESS Newswire
News headline image
Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record
February 19, 2026
Via ACCESS Newswire
News headline image
Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))
February 17, 2026
Via ACCESS Newswire
News headline image
Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors
February 13, 2026
Via ACCESS Newswire
News headline image
Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))
February 12, 2026
Via ACCESS Newswire
News headline image
Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements
February 11, 2026
Via ACCESS Newswire
News headline image
Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
February 10, 2026
Via ACCESS Newswire
News headline image
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit
February 05, 2026
Via ACCESS Newswire
News headline image
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution
February 03, 2026
Via ACCESS Newswire
News headline image
Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity
January 22, 2026
Via ACCESS Newswire
News headline image
Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign
January 21, 2026
Via ACCESS Newswire
News headline image
Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief
January 20, 2026
Via ACCESS Newswire
News headline image
Aspire Biopharma Announces Reverse Stock Split
January 14, 2026
Via ACCESS Newswire
News headline image
Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)
January 07, 2026
Via ACCESS Newswire
News headline image
Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine
December 18, 2025
Via ACCESS Newswire
News headline image
Brookmount Gold (OTC: BMXI) Profitable Q3 2025, Gold Production, Spinoff Dividends Takes Shape – More Stocks Inside
December 15, 2025
Via AB Newswire
News headline image
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
December 12, 2025
Via ACCESS Newswire
News headline image
Aspire Biopharma Provides Q3 2025 Business Update
December 04, 2025
Via ACCESS Newswire
News headline image
Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)
December 02, 2025
Via ACCESS Newswire
News headline image
Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member
November 26, 2025
Via ACCESS Newswire
News headline image
Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin
November 06, 2025
Via ACCESS Newswire
News headline image
Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform
October 06, 2025
Via ACCESS Newswire
News headline image
Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025
October 03, 2025
Via ACCESS Newswire
News headline image
TOMI Environmental (NASDAQ: TOMZ) Expands SteraMist – Protecting People from Germs, Viruses & Biohazards | More Stocks Inside
October 01, 2025
Via AB Newswire
Topics Artificial Intelligence
News headline image
Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication
October 01, 2025
Via ACCESS Newswire
News headline image
Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product
September 17, 2025
Via ACCESS Newswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap